Table 1.

Summary of eligible studies considered in the meta-analysis

First author(year)	Country	Ethnicity	Cancer type	Type of study	Case no.	Control no.	C Allele frequency (%) case/control
Kuschel(2002)[1]	Germany	Caucasians	Breast cancer	Population-based	1694	734	34.3/32.2
Forsti(2004)[20]	Finland	Caucasians	Breast cancer	Population-based	223	319	35.7/38.6
Millikan (2005)[41]	North Carolina	African-American	Breast cancer	Hospital-based	726	681	25.1/23.6
Millikan (2005)[41]	North Carolina	Caucasians	Breast cancer	Hospital-based	1273	1136	31.6/32.3
Lu(2006)[21]	USA	Caucasians	Breast cancer	Hospital-based	421	423	35.9/29.7
Zhang (2005)[42]	China	Chinese	Breast cancer	Hospital-based	220	310	35.9/38.2
Lan(2005)[18]	China	Chinese	Lung cancer	Population-based	118	111	57.2/66.7
Ryk (2006)[43]	Sweden	Caucasians	Lung cancer	Hospital-based	177	152	-/-
Zienoldding (2006)[44]	Norway and of Norwagian	Caucasians	Lung cancer	Hospital-based	376	310	34.4/28.5
Broberg (2005)[16]	Sweden	Caucasians	Bladder cancer	Hospital-based	61	154	36.1/37.3
Sanyal (2004)[45]	Sweden	Caucasians	Bladder cancer	Hospital-based	299	278	38.5/34.2
Figueroa(2007)[48]	Spanish	Caucasians	Bladder cancer	Hospital-based	1086	1020	31.8/30.0
Festa (2005)[17]	Sweden and Finland	Caucasians	Basal cell carcinoma	Hospital-based	241	574	37.1/36.8
Thirumaran (2006)[46]	Hungary, Romania, and Slovakia	Caucasians	Basal cell carcinoma	Hospital-based	529	533	35.6/32.4
Auranen (2005)[13]	Combined*	Caucasians	Ovarian cancer	Mixed§	1586	2685	32.7/33.3
Hebbring (2006)[47]	Finland	Caucasians	Prostate cancer	Population-based	200	200	35.5/35.8
Pardini (2008)[49]	Czech Republic	Caucasians	Colorectal cancer	Hospital-based	532	532	31.8/34.0

*: United Kingdom SEARCH study. Danish MALOVA study. United States FROC study. United Kingdom Royal Marsden Hospital and young ovarian cancer study (UK RMH/YOV).

^§: Subjects including population and hospital source.